Just more than a month after the FDA approved their first biosimilar to ustekinumab (Stelara), Bio-Thera Solutions announced positive results from their phase 3 trial of BAT2206
Bio-Thera Solutions Announces Positive Results From Phase 3 Study Of BAT2206, A Proposed Biosimilar Referencing Stelara® menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Bio-Thera Solutions, Ltd. (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative assets,.
Durability of Booster mRNA Vaccine against SARS-CoV-2 BA 2 12 1, BA 4, and BA 5 Subvariants nejm.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nejm.org Daily Mail and Mail on Sunday newspapers.